465 related articles for article (PubMed ID: 16353168)
1. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
4. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
[TBL] [Abstract][Full Text] [Related]
8. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Levine DA; Bogomolniy F; Yee CJ; Lash A; Barakat RR; Borgen PI; Boyd J
Clin Cancer Res; 2005 Apr; 11(8):2875-8. PubMed ID: 15837735
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
Lai YL; Mau BL; Cheng WH; Chen HM; Chiu HH; Tzen CY
Ann Surg Oncol; 2008 Apr; 15(4):1064-9. PubMed ID: 18183466
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the PIK3CA gene in ovarian and breast cancer.
Campbell IG; Russell SE; Choong DY; Montgomery KG; Ciavarella ML; Hooi CS; Cristiano BE; Pearson RB; Phillips WA
Cancer Res; 2004 Nov; 64(21):7678-81. PubMed ID: 15520168
[TBL] [Abstract][Full Text] [Related]
11. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in breast cancer are associated with poor outcome.
Li SY; Rong M; Grieu F; Iacopetta B
Breast Cancer Res Treat; 2006 Mar; 96(1):91-5. PubMed ID: 16317585
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations in advanced ovarian carcinomas.
Wang Y; Helland A; Holm R; Kristensen GB; Børresen-Dale AL
Hum Mutat; 2005 Mar; 25(3):322. PubMed ID: 15712344
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.
Lee JW; Soung YH; Kim SY; Lee HW; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Oncogene; 2005 Feb; 24(8):1477-80. PubMed ID: 15608678
[TBL] [Abstract][Full Text] [Related]
16. Diffuse growth pattern affects E-cadherin expression in invasive breast cancer.
Brinck U; Jacobs S; Neuss M; Tory K; Rath W; Kulle B; Füzesi L
Anticancer Res; 2004; 24(4):2237-42. PubMed ID: 15330167
[TBL] [Abstract][Full Text] [Related]
17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
18. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
19. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
Intra M; Rotmensz N; Viale G; Mariani L; Bonanni B; Mastropasqua MG; Galimberti V; Gennari R; Veronesi P; Colleoni M; Tousimis E; Galli A; Goldhirsch A; Veronesi U
Cancer; 2004 Sep; 101(5):905-12. PubMed ID: 15329896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]